Trial Profile
Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 May 2017 Status changed from active, no longer recruiting to completed.
- 17 May 2017 Status changed from active, no longer recruiting to completed.
- 22 Jan 2016 Results published in the Annals of Oncology